- ￥985.60
- LC labs
- 美国
- A-1107
- 2025年07月10日
16 年钻石会员
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
见说明书
- 保质期：
＞1年
- 英文名：
Axitinib Free Base
- 库存：
期货2-3周
- 供应商：
上海经科化学科技有限公司
- CAS号：
319460-85-0
- 规格：
50mg
供应商：上海经科化学科技有限公司
服务热线：400-0199-638
QQ:472482400(上海经科）
微信号：shjkchem
活动：消费积分可换充值卡！
本试剂(Axitinib)
仅供科研实验使用,不得用于其他用途！
货 号：A-1107
名 称：Axitinib
别 名：Axitinib Free Base
C A S ：319460-85-0
分子量：386.47
分子式：C22H18N4OS
纯 度：HPLC/TLC:>99%
说 明：Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 33 mg/mL; soluble in ethanol at 1.7 mg/mL with warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 10-50 µM; buffers, serum, or other additives may increase or decrease the aqueous solubilit. Disposal: A.
文 献：Axitinib inhibited growth of breast tumors in vivo at doses of 10-100 mg/kg and disrupted tumor microvasculature as measured by dynamic contrast-enhanced MRI. Wilmes, L.J., et al. "AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging." Magn. Reson. Imaging. 25: 319-327 (2007). Regrowth of blood vessels in spontaneous RIP-Tag2 tumors and implanted Lewis lung carcinomas in mice was studied after being treated with axitinib or AG-028262 for 7 days. Both agents inhibited 50%-60% of tumor neovasculature formation. Empty sleeves of basement membrane were left behind and surviving pericytes had less α-SMA immunoreactivity. Endothelial sprouts grew into empty sleeves of basement membrane one day after drug withdrawal, which was followed by vessel patency and connection to the bloodstream. Tumors were fully revascularized and the pericyte phenotype returned to baseline by 7 days. Mancuso, M.R., et al. "Rapid vascular regrowth in tumors after reversal of VEGF inhibition." J. Clin. Invest. 116: 2610-2621 (2006). Axitinib inhibited angiogenesis significantly in rat 9L tumors grown s.c. in scid mice but only delayed tumor growth moderately. A combination of axitinib with metronomic cyclophosphamide completely blocked 9L tumor growth on initiation of drug treatment. However, metronomic cyclophosphamide alone required multiple treatment cycles to inhibit tumor growth. Ma, J. and Waxman, D.J. "Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib." Mol. Cancer Ther. 7: 79-89 (2008). Axitinib has clinical activity in patients with cytokine-refractory metastatic renal-cell cancer. Rixe, O., et al. "Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study." Lancet Oncol. 8: 975-984 (2007).
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验相关实验
Sci Adv：张华团队阐明成年卵巢血管新生模式并提出延缓生殖衰老新策略
示了卵巢中卵泡周期募集过程中进行优势选择的可能结构基础。 基于机制研究中所揭示的生长卵泡是成年卵巢血管新生的发生中心这一模式特征，该研究进一步地探索了抑制卵巢血管新生对延缓雌性卵泡发育的可能性。通过对小鼠腹腔注射合适剂量的血管新生抑制药物 Axitinib[5]，研究表明 Axitinib 可有效地抑制不同年龄小鼠的成年卵巢血管新生并对基础血管网络无明显影响。并且，卵巢血管新生的抑制，明显地达到了减缓卵巢生殖储备消耗的现象目的。 机制研究表明，适当抑制成年卵巢血管新生可暂停卵巢发育，从而延长卵巢
技术资料暂无技术资料 索取技术资料
Axitinib
￥985.60
